Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 14.12.2021
Formycon AG
Press Release // December 14, 2021
MS Pharma becomes Partner for the Commercialization of FYB201, Formycon's Biosimilar Candidate to Lucentis(R)1 (ranibizumab), in the MENA Region
Munich - Bioeq AG ("Bioeq"), licensee and exclusive holder of the worldwide commercialization rights for FYB201, Formycon's biosimilar candidate for Lucentis(R) (ranibi [ … ]
Thu, 09.12.2021
Formycon AG
Press Release // December 9, 2021
Formycon and Scientists from TUM publish new Data on broadly effective SARS-CoV-2 antiviral Drug FYB207
- Joint study describes optimized ACE2-IgG4-Fc fusion proteins
- Picomolar Neutralization of the SARS-CoV-2 variants of concern
- Neutralizing effect of SARS-CoV-2 delta variant confirmed
- High efficacy [ … ]
Tue, 09.11.2021
Formycon AG
Press Release // November 9, 2021
Formycon Reports its Nine-Month Figures for 2021
- Strong topline growth to Euro 29.1 million compared to previous year
- Forecast for full-year revenues concretized and raised to around Euro 40 million
- EBITDA of Euro -10.0 million and net result for the period of Euro -10.7 million in line with plans
- [ … ]
Tue, 19.10.2021
Formycon AG
Press Release // October 19, 2021
Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon's COVID-19 Drug FYB207
- Agreement aims to accelerate development and commercialization of FYB207 in the Asia-Pacific region
- SCG Cell Therapy receives exclusive license to develop, manufacture and commercialize FYB207 i [ … ]
Mon, 18.10.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // October 18, 2021
Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and SCG Cell Therap [ … ]
Fri, 01.10.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // October 1, 2021
Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) [ … ]
Mon, 27.09.2021
Formycon AG
Press Release // September 27, 2021
Formycon Reports on Virtual Annual General Meeting 2021
- Shareholders approve all items on the agenda
- Management Board reports in detail on ongoing development projects
- Supervisory Board and Management Board ratified by a large majority
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) held its [ … ]
Thu, 23.09.2021
Formycon
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes stuft die Aktie auf BUY
herauf und bestätigt sein Kursziel von EUR 78,00.
Zusammenfassung:
Die Umsatzerlöse in H1/21 in Höhe von €20,3 Mio. (FBe €21,0 Mio.; H1/20:
€16,5 Mio.) lagen nah [ … ]
Tue, 21.09.2021
Formycon AG
Press Release // September 21, 2021
Formycon Publishes Half-Year Results for 2021
- Group turnover above H1 half-year level at Euro 20.3 million
- EBITDA of Euro -9.7 million and half-year results of Euro -10.2 million in line with plans
- Result due to investments in the non-partnered projects FYB206 and FYB207
- Significant progress in th [ … ]
Wed, 15.09.2021
Formycon AG
Press Release // September 15, 2021
Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug developme [ … ]